Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study

Fig. 3The alternative text for this image may have been generated using AI.

Kaplan–Meier Survival Analysis. Kaplan–Meier curves comparing (a) overall survival (OS), (b) event-free survival (EFS), and (c) recurrence-free survival (RFS) between the LEN-TAP and TACE cohorts. TACE, transarterial chemoembolization; LEN-TAP, lenvatinib plus TACE and anti-PD-1 inhibitors

Back to article page